Consistent with these findings, previous studies performed in BRAFV600E-driven melanoma cells showed that BRAF inhibitor vemurafenib triggers ER stress and increases ATF4 expression by increasing the cytosolic Ca2+ [40]. This evidence concerns the gene ATF4 and melanoma.